Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
June 10, 2022 08:00 ET | Vor Biopharma
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
June 01, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
May 12, 2022 16:15 ET | Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Two Upcoming Investor Conferences
May 05, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
April 25, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Announces Retirement of Chief Medical Officer
April 14, 2022 16:15 ET | Vor Biopharma
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
March 14, 2022 16:30 ET | Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Three Upcoming Investor Conferences
February 28, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Two Upcoming Investor Conferences
January 04, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...